Brokers Set Expectations for OptiNose FY2029 Earnings

OptiNose, Inc. (NASDAQ:OPTN) – HC Wainwright issued their FY2029 earnings estimates for shares of OptiNose in a note issued to investors on Friday, January 3rd. HC Wainwright analyst M. Caufield forecasts that the company will earn $1.41 per share for the year. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for OptiNose’s current full-year earnings is ($0.20) per share.

Separately, Piper Sandler cut their price objective on shares of OptiNose from $45.00 to $15.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th.

OptiNose Stock Performance

OPTN stock opened at $6.12 on Monday. The stock’s 50 day simple moving average is $7.69 and its 200 day simple moving average is $11.70. The company has a market cap of $61.57 million, a P/E ratio of -21.86 and a beta of -0.15. OptiNose has a fifty-two week low of $4.82 and a fifty-two week high of $31.50.

Institutional Trading of OptiNose

A number of institutional investors and hedge funds have recently modified their holdings of the business. GSA Capital Partners LLP bought a new position in OptiNose in the 3rd quarter valued at $61,000. XTX Topco Ltd bought a new position in OptiNose during the second quarter valued at $88,000. Squarepoint Ops LLC lifted its position in shares of OptiNose by 173.7% during the 2nd quarter. Squarepoint Ops LLC now owns 171,610 shares of the company’s stock valued at $178,000 after buying an additional 108,903 shares during the last quarter. State Street Corp lifted its position in shares of OptiNose by 14.2% during the 3rd quarter. State Street Corp now owns 341,303 shares of the company’s stock valued at $229,000 after buying an additional 42,500 shares during the last quarter. Finally, Rice Hall James & Associates LLC increased its holdings in OptiNose by 15.4% in the 3rd quarter. Rice Hall James & Associates LLC now owns 1,140,626 shares of the company’s stock worth $764,000 after acquiring an additional 152,435 shares during the last quarter. 85.60% of the stock is owned by hedge funds and other institutional investors.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.